Graphic with headshots of Drs. McCreedy, Sadarangani, and Zimmerman from the shoulders up, next to the words "Grand Rounds & Podcast. January 2024"

Strategies to Implement ePCTs in Home and Community-Based Settings – Issues and Successes in Assisted Living and Adult Day Centers

January 2024 – In Grand Rounds 43, Drs. McCreedy, Sadarangani, and Zimmerman note common challenges that arise when conducting ePCTs in home and community-based, long-term care settings and suitable solutions to address these challenges.

Download Webinar Slides

 

Ellen McCreedy, PhD

Assistant Professor

Brown University School of Public Health

 

Tina Sadarangani,
PhD, RN

Associate Professor

NYU Rory Meyers College of Nursing

Sheryl Zimmerman, PhD

University Distinguished Professor

University of North Carolina at Chapel Hill

Learning Objectives

  • Understand the national scope of assisted living and adult day centers (i.e., home and community-based settings)
  • Recognize common challenges conducting ePCTs in home and community-based settings
  • Be familiar with strategies to address challenges conducting ePCTs in home and community-based settings
Graphic with headshots of Drs. O'Brien and Fowler from the shoulders up, next to the words "Grand Rounds & Podcast. December 2023"

The Clinical Implementation of Alzheimer’s Disease Biomarkers

December 2023 – In Grand Rounds 42, Drs. O'Brien and Fowler engage in a discussion regarding the landscape of Alzheimer's disease (AD) biomarker testing, dive into the potential clinical usefulness of plasma AD biomarkers, and identify the obstacles that hinder the implementation of plasma AD biomarkers.

Download Webinar Slides

Speakers

Kyra S. O'Brien, MD
Kyra S. O'Brien, MD

Assistant Professor of Neurology

Penn Memory Center, University of Pennsylvania

Nicole Fowler, PhD, MHSA
Nicole Fowler, PhD, MHSA

Associate Professor of Medicine

Indiana University School of Medicine

Learning Objectives

  • Understand the landscape of Alzheimer’s disease (AD) biomarker testing.
  • Describe the potential clinical utility of plasma AD biomarkers.
  • Identify barriers to plasma AD biomarker implementation in specialist and non-specialist settings.